BRDT Inhibitors
JQ1, NHWD870, CDD-1102
- User: Male
- Hormonal: Non-Hormonal
-
Delivery type:
- Not Yet Determined
-
Intended Duration:
- Not Yet Determined
- Development Stage: Pre-Clinical
- Developer(s)/researcher(s): Cornell University, Baylor College of Medicine, Nantong University, Sichuan University, University of Minnesota
Details
- API: Not Yet Determined - Multiple Compounds in Development
- Target: BRDT
-
Mechanism of Action:
- Reduced Sperm Production
- Inhibition of Sperm Motility
- Inactive Materials: Not Yet Determined
- Regimen: Not Yet Determined
- MPT: Not Potential MPT
- Promising Attributes: Early studies on lead compounds indicate potential for reversibility, which market research indicates is likely to be a desirable product characteristic for male users
Product Status
Active Pre-Clinical Research
History
April 2022: Researchers from Baylor used their collection of DNA-encoded chemical libraries to identify BET BD1-selective inhibitors that have promise as potential male contraceptives.
July 2022: Nantoing University researchers use single-cell RNA sequencing and gene ontology to reveal that JQ1 had the ability to regulate gene transcription by changing chromatin conformation in mouse spermatogenesis.
Sept 2022: Scientists at Sichaun University find that the BET family inhibitor NHWD870 can produce a good contraceptive effect through animal experiments in vivo, and the fertility can be restored to normal after drug withdrawal.
2025: Cornell University publishes additional evaluation of JQ1 for BRDT inhibition, reporting that daily injections in animals disrupted spermatogenesis and the ability to sire pups, with partial restoration of sperm function 6 weeks post-cessation and full restoration over time. Parallel evaluation by a coalition of Indian universities led by Kasturba Medical College Manipal identified JQ1's potential as a non-hormonal female contraceptive through similar mechanisms as its use in males.